Celcuity (NASDAQ:CELC) had its price target lifted by Craig Hallum from $30.00 to $35.00 in a research report released on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock.

Celcuity stock traded down $0.25 during mid-day trading on Wednesday, hitting $25.48. The company’s stock had a trading volume of 20,648 shares, compared to its average volume of 19,058. Celcuity has a one year low of $13.16 and a one year high of $31.00.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.03.

In other news, Director Richard Nigon bought 9,747 shares of the stock in a transaction on Tuesday, September 11th. The stock was acquired at an average cost of $22.31 per share, for a total transaction of $217,455.57. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 43.50% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its stake in shares of Celcuity by 58.3% during the 3rd quarter. Acadian Asset Management LLC now owns 4,797 shares of the company’s stock worth $138,000 after purchasing an additional 1,766 shares during the last quarter. California Public Employees Retirement System purchased a new stake in shares of Celcuity during the 2nd quarter worth $248,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Celcuity during the 2nd quarter worth $271,000. Bank of New York Mellon Corp purchased a new stake in shares of Celcuity during the 2nd quarter worth $291,000. Finally, Carlson Capital Management purchased a new stake in Celcuity in the second quarter valued at about $295,000. Hedge funds and other institutional investors own 14.62% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer.

See Also: Average Daily Trade Volume – What You Need to Know

The Fly

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.